Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00291668
Status:
COMPLETED
Last Update Posted:
2020-08-03
First Post:
2006-02-10
Brief Title:
Clinical Study of CDP870Certolizumab Pegol in Patients With Active Crohns Disease
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Phase II Multi-center Double-blind Placebo-controlled Parallel-group Dose-response Study to Assess the Safety and Efficacy of CDP870Certolizumab Pegol Dosed Subcutaneously in Patients With Active Crohns Disease
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-centre randomized double-blind dose response clinical study of CDP870 in patients with Crohns disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2014-004399-42 | EUDRACT_NUMBER | None | None |